CompletedPhase 2

Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.

Denmark, Norway, Sweden23 participantsStarted 2007-06

Plain-language summary

The purpose of this study is to investigate the effect of up to 200 mg of PF-00446687 on acute sexual arousal and sexual interest in post menopausal females, as well as examining the safety and toleration of the drug.

Who can participate

Age range45 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women who have evidence of Female Sexual Arousal Disorder. * Women who experience personal distress due to Female Sexual Dysfunction. * Post menopausal women aged between 45 and 65 years. Exclusion Criteria: * Women whose sexual dysfunction is limited to certain types of stimulation, situation or specific partners. * Women who experience pain with sexual intercourse or who have a sexual aversion disorder. * Women suffering from female sexual dysfunction where the cause is treatable, for example inadequately controlled diabetes or thyroid dysfunction.

What they're measuring

Assess effect of single doses of PF-00446687 on acute sexual arousal and sexual interest, using questionnaires, in post menopausal women suffering from Female Sexual Dysfunction. A diary will be completed for 7 days following the 3 dosing days.

Timeframe: From day of dosing until 7 days post-dose

Trial details

NCT IDNCT00479570

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-02

View on ClinicalTrials.gov More Female Sexual Dysfunction trials